Practice Matters
Value Assessment of Oncology Pharmacist Interventions
Mallika P. Patel, PharmD, CPP, Sally Y. Barbour, PharmD, BCOP, CPP, FHOPA, and Meredith T. Moorman, PharmD, BCOP, CPP
From Department of Pharmacy, Duke University Hospital, Durham, North Carolina
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Mallika P. Patel, PharmD, CPP, Duke University Medical Center, 052A Baker House, Trent Drive, Durham, NC 27710
E-mail: mallika.patel@duke.edu
J Adv Pract Oncol 2023;14(4):329–331 |
https://doi.org/10.6004/jadpro.2023.14.4.7 |
© 2023 Harborside™
ABSTRACT
A review of the published literature confirms the challenge in quantifying the value of oncology pharmacists. This editorial expands on a 2020 study by Meleis and colleagues published in the Journal of the Advanced Practitioner in Oncology and seeks to correlate pharmacist interventions to cost-saving and cost-avoidance measures to show the value of ambulatory oncology clinical pharmacists in patient care. A total of 4,686 interventions were reviewed. The 6-month intervention data demonstrate an annualized value of approximately $1.1 million dollars from nine ambulatory oncology clinical pharmacists showcasing the essential role of the clinical pharmacist in ambulatory oncology settings.
For access to the full length article, please
sign in.
